DILI
Conditions
Interventions
Treatment Group (Dicyclic alcohol (25mg/ tablet)):N/A
Control Group (Polyene phosphatidylcholine capsule (228mg/ tablet)):N/A
Sponsors
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Subjects who completed the 4-week follow-up period of the multicenter, randomized, double-blind, positive controlled Phase iii clinical trial of dicyclol tablets in the treatment of acute drug-induced liver injury; The subject can understand and sign the informed consent after fully understanding the nature of the study, the nature of his disease, and the risks that may be borne by participating in the study.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome evevts, Including complete recovery of liver injury, recurrence of acute liver injury, conversion to chronic liver injury or delayed recovery of liver injury, occurrence of acute liver failure and death; | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome evevts, Including complete recovery of liver injury, recurrence of acute liver injury, conversion to chronic liver injury or delayed recovery of liver injury, occurrence of acute liver failure and death;the occurrence of liver injury reactivation;The normalization rate of serum ALT; | — |
Countries
China
Contacts
Public ContactYimin Mao
Renji Hospital, SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE
Outcome results
None listed